PanCytoVir™ (oral probenecid)
COVID-19
About TrippBio
TrippBio is a clinical-stage biotech leveraging drug repurposing to develop host-targeted antiviral therapies for respiratory diseases. Its lead asset, PanCytoVir™ (oral probenecid), has demonstrated positive Phase 2 results in COVID-19 and is being advanced for influenza, with a strategy targeting multiple viruses like RSV. The company is led by an experienced team with deep drug development expertise and operates as a private, pre-revenue entity aiming to bring life-saving treatments to market efficiently.
View full company profileAbout TrippBio
TrippBio is a clinical-stage biotech leveraging drug repurposing to develop host-targeted antiviral therapies for respiratory diseases. Its lead asset, PanCytoVir™ (oral probenecid), has demonstrated positive Phase 2 results in COVID-19 and is being advanced for influenza, with a strategy targeting multiple viruses like RSV. The company is led by an experienced team with deep drug development expertise and operates as a private, pre-revenue entity aiming to bring life-saving treatments to market efficiently.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |